Genentech Debuted Documentary on Company History
The 35-minute film chronicles the biotech firm’s growth since its founding 50 years ago.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies more when they share patient-centered stories about their history?
Genentech premiered a documentary titled The Impossible Bet in New York City on October 5, 2026. The film uses archival footage and patient interviews to explore the company’s history.
Why it matters
The company created this project to share its corporate history and build public trust as it prepares to enter new markets, including obesity and cardiovascular disease treatment.
The documentary features a 35-minute run time and highlights company milestones from the last 50 years, including the 1998 regulatory approval of the drug Herceptin.
The players
Genentech
This biotechnology corporation is headquartered in San Francisco and is known for its role in the development of monoclonal antibodies.
Herbert Boyer
He is a co-founder of Genentech and a pioneering figure in the field of recombinant DNA technology.
Laurie May
She is a long-standing employee who joined Genentech 47 years ago as the firm's 35th hire.
The details
Produced in collaboration with The New York Times T Brand Studio and Brother Films, the documentary includes reflections from company executives, patient stories, and Max Boyer, daughter of co-founder Herbert Boyer. Genentech is currently promoting the film with billboards located in Times Square.
Timeline
1976: Genentech was founded.
1998: Herceptin received regulatory approval.
2009: The patient Janet was diagnosed with breast cancer.
2024: Max Boyer was interviewed for the film.
October 5, 2026: The documentary premiered in New York City.
The Tech Race
The firm’s focus on the development of Herceptin serves as the primary historical anchor for its legacy in specialized medicine. This branding effort signals a strategic pivot as the company works to position itself in the competitive obesity and cardiovascular disease sectors.
Consumers may see increased brand visibility for the company through large-scale marketing campaigns in major hubs like Times Square. This effort is designed to build brand familiarity as the company moves into new therapeutic areas that could eventually impact patient treatment options.
The takeaway
The documentary marks a shift in Genentech’s corporate communications as it seeks to translate five decades of scientific milestones into consumer confidence. This strategy highlights the importance of narrative storytelling for established biotech firms entering new disease markets.
Further reading
For more on the industry, visit the Biotech section.
Source note: This article includes information reported by FiercePharma.
Live Poll
Do you trust pharmaceutical companies more when they share patient-centered stories about their history?
